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Background. Nitric oxide (NO) is an important vascular signaling molecule that plays a role in vascular homeostasis. A reduction in
NO bioavailability is thought to contribute to endothelial dysfunction, an early risk factor for both cardiovascular disease and type 2
diabetes. Dietary nitrate, through the nitrate-nitrite-NO pathway, may provide an alternate source of NO when the endogenous
eNOS system is compromised. In addition to a role in the vascular system, NO may also play a role in the metabolic syndrome
including obesity and glucose tolerance. Aim. To investigate the effect of long-term dietary nitrate supplementation on
development of the metabolic syndrome in mice fed a high-fat diet. Methods. Following 1 week of acclimatisation, male (6–8
weeks) C57BL6 mice were randomly assigned to the following groups (10/group) for 12 weeks: (i) normal chow+NaCl (1mmol/
kg/day), (ii) normal chow+NaNO3 (1mmol/kg/day), (iii) high-fat diet +NaCl (1mmol/kg/day), and (iv) high-fat diet + NaNO3
(1mmol/kg/day). Body weight and food consumption were monitored weekly. A subset of mice (5/group) underwent running
wheel assessment. At the end of the treatment period, all mice underwent fasting glucose tolerance testing. Caecum contents,
serum, and tissues (liver, skeletal muscle, white and brown adipose, and kidney) were collected, frozen, and stored at −80°C
until analysis. Results. Consumption of the high-fat diet resulted in significantly greater weight gain that was not affected by
dietary nitrate. Mice on the high-fat diet also had impaired glucose tolerance that was not affected by dietary nitrate. There
was no difference in adipose tissue expression of thermogenic proteins or energy expenditure as assessed by the running wheel
activity. Mice on the high-fat diet and those receiving dietary nitrate had reduced caecum concentrations of both butyrate and
propionate. Conclusions. Dietary nitrate does not prevent development of the metabolic syndrome in mice fed a high-fat diet.
This may be due, in part due, to reductions in the concentration of important short-chain fatty acids.
1. Introduction
Nitric oxide (NO) is an important vascular signaling mole-
cule that plays a major role in the control of vascular
function and tone [1]. The majority of the body’s NO is
synthesised endogenously through conversion of L-arginine
to citrulline by endothelial cell-derived nitric oxide synthase
(eNOS). Once released, NO diffuses to the underlying
smooth muscle cells and stimulates the production of cyclic
guanosine monophosphate (cGMP) and subsequent relaxa-
tion of the vessel wall. A reduction in the bioactivity and/
or bioavailability of endogenously-derived NO is thought
to be the main cause of endothelial dysfunction, an early risk
factor for cardiovascular disease (CVD) and type 2 diabetes
(T2DM) [2].
There is substantial epidemiological evidence to suggest
that diets rich in fruits and vegetables have beneficial effects
on CVD and its risk factors [3]. Dietary nitrate (NO3
−),
found predominantly in green leafy vegetables, may be one
of the beneficial components of such a diet as it represents
an alternative source of NO. Dietary nitrate is well absorbed,
and approximately 25% of ingested nitrate is secreted into the
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saliva and 20% of this (~5% of ingested nitrate) is converted
to nitrite (NO2
−) by bacteria in the mouth. The nitrite is then
swallowed and absorbed where it can be stored to act as a pool
of NO or have direct vasodilatory effects [4]. This nitrate/
nitrite-derived NO pool represents a NOS-independent path-
way that can be used to supplement endogenous NO supplies
or replace them when they are compromised.
The metabolic syndrome is classified as a cluster of risk
factors that include hypertension, obesity, impaired glu-
cose/insulin tolerance, and dyslipidaemia, and is a significant
contributor to the development of both CVD and type 2
diabetes [5]. Endothelial dysfunction is often present in the
metabolic syndrome, and studies have shown that reduced
NO production and/or bioavailability has a role in the path-
ogenesis of many risk factors associated with the condition
[6]. We have previously shown that low and moderate dose
dietary nitrate can prevent endothelial dysfunction and
improve plaque composition and stability in the ApoE−/−
mouse [7]. Dietary nitrate has also been shown to reduce
triglycerides and improve intravenous glucose tolerance in
eNOS-deficient mice [8]. Additionally, nitrate has been
shown to induce antiobesity effects, including weight loss
and reductions in body fat, via increases in the expression
of thermogenic genes in brown adipose tissue [9]. Despite
this, there is little evidence examining the effect of long-
term dietary nitrate supplementation on the development
of features of the metabolic syndrome. Therefore, the aim
of the present study was to investigate the effect of long-
term dietary nitrate supplementation on weight gain, glucose
and insulin tolerance, and indices of thermogenesis in
C57BL6 mice fed a high-fat diet.
2. Methods
2.1. Animal Study.Male C57BL6 mice (6–8) weeks were pur-
chased from the Animal Resource Centre (Perth, Australia)
and maintained at 23± 2°C under a 12-hour light–dark cycle.
Following a week of acclimatisation, the mice were randomly
divided into one of four groups (n = 10, 5 mice/cage): (i)
normal chow+NaCl-supplemented water (1mmol/kg/day),
(ii) normal chow+NaNO3-supplemented water, (iii) high-
fat diet +NaCl-supplemented water (1mmol/kg/day), and
(iv) high-fat diet +NaNO3-supplemented water (1mmol/
kg/day). The normal chow diet was commercial rodent chow
consisting of 4.8% wt/wt fat, while the high-fat diet (HFD)
contained 23.5% wt/wt fat (clarified butter). The nitrate dose
is both physiologically relevant and comparable to the dose
previously used where we observed beneficial effects on both
vascular function and atherosclerotic plaque composition
[7]. Mice were allowed ad libitum access to water and food,
with all diets prepared by Specialty Feeds (Glenn Forrest,
Australia). The level of nitrate and nitrite in the food pellet
was 9.9μg/g and 0.8μg/g, respectively [7]. The mice were
maintained on their respective diets for 12 weeks. Body
weight and food intake were measured weekly. The study
was approved by the Royal Perth Hospital Animal Ethics
Committee (R534/17-18) with reciprocal approval from
Curtin University Animal Ethics Committee. All animal
experiments were compliant with the National Health and
Medical Research Council (NHMRC) guidelines for the Care
and Use of Laboratory Animals in Australia.
2.2. Glucose Tolerance Tests. Intraperitoneal glucose toler-
ance tests (IPGTT) were performed on fasting (5 hr) mice
at week 11. To measure blood glucose levels, blood sam-
ples were taken from the tail of fasting (5 hr) mice before
(t = 0 min) and at subsequent time intervals of t = 15, 30,
45, 60, 90, and 120 min following intraperitoneal administra-
tion of 1 g glucose/kg. Blood glucose levels were measured
using Accu-Chek Performa Strips and Glucometer (Roche
Diagnostics, Australia). The area under the curves (AUCs)
was calculated using the trapezoidal method.
2.3. Tissue Histology and Pathology. Fasted (5 hr) mice were
anaesthetised with methoxyflurane at week 12, and liver
and white adipose tissues were collected and fixed in 4%
formaldehyde overnight before being incubated in 50%
ethanol and embedded in paraffin. The tissues were then
cut into 4μm sections and stained with hematoxylin and
eosin (CellCentral, UWA) before being visualized and photo-
graphed using a Nikon Eclipse TS100 microscope. Additional
liver, white and brown adipose tissues, gastrointestinal tract,
kidney, and skeletal muscle were collected and snap frozen
in liquid nitrogen and stored at −80°C until analysis. White
and brown adipose tissue protein expression of AMPK (Cell
Signaling, USA), phosphorylated AMPK (Cell Signaling,
USA), ACC (Cell Signaling, USA), phosphorylated ACC
(Cell Signaling, USA), and UCP-1 (Cell Signaling, USA) were
determined using western blot and normalised to actin
(Sigma, USA), as previously described [7]. In a subset of mice
(5/group), kidneys were also collected and stained with
antisodium glucose cotransporter 2 (SGLT2, Santa Cruz
Biotechnology) as previously described [10].
2.4. Energy Expenditure. Subsets of mice (5/treatment group)
were housed individually with wireless running wheels
during week 10 of the treatment period. Each mouse was
allowed free access to their running wheel, which collected
data on behaviour and activity, assessed as wheel revolutions
and distance covered by the mouse using the Running
Wheel Manager Acquisition Software (Med Associates
Inc.). Individual mice were housed with their wheel for a
period of 6 days. The first 3 days were an acclimatisation
period with all measurements discarded from final analysis.
The final 3 days of activity were collected and averaged using
the Wheel Analysis Software (Med Associates Inc.) to pro-
vide information on daily activity level and mean overall
activity level.
2.5. Caecum Short-Chain Fatty Acid (SCFA) Analysis. Cae-
cum samples isolated from the gastrointestinal tract were col-
lected and snap frozen in liquid nitrogen and stored at −80°C
until analysis. SCFA concentrations of acetate, butyrate, and
propionate were analysed using gas chromatography–mass
spectrometry as previously described [11].
2.6. Serum Nitrate/Nitrite Concentrations. Fasted (5 hr) mice
were anaesthetised with methoxyflurane at week 12, and
blood samples were obtained via cardiac puncture. Serum
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was separated via centrifugation (3000 rpm, 4°C, 10mins)
and stored at −80°C until analysis. Nitrate and nitrite concen-
trations were determined using gas chromatography–mass
spectrometry (GC–MS) as previously described [12].
2.7. Statistical Analysis. Statistical analysis was performed
using SPSS (version 21.0). All values are expressed as mean
± standard error (SEM). Data was analysed using repeated
measures analysis of variance (ANOVA) and one-way
ANOVA with Tukey post hoc analysis to determine differ-
ences between groups. A p < 0 05 was determined to be of
statistical significance. The data used to support the findings
of this study are available from the corresponding author
upon request.
3. Results
3.1. Nitrate Diet and the Effect of Dietary Nitrate on Obesity,
Hepatic Fat, and Food Intake. Previous studies suggest mice
consume approximately 5 g of chow and 6mL of water per
day [13]. Our previous nitrate study demonstrated that water
supplemented with 1mmol of nitrate contains 130μg/mL of
nitrate and 3μg/mL of nitrite [7]. In the present study, mice
consuming the HFD gained significantly more weight over
12 weeks compared tomice consuming the normal chow diet.
The addition of nitrate had no effect on weight gain when
added to either the normal chow or HFD (Figure 1(a)). Aver-
age food consumption (g/mouse/day) was lower in mice
consuming the HFD compared to normal chow. When
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Figure 1: (a) Body weight gain, (b) adipocyte hypertrophy, and (c) hepatic lipid droplet accumulation in C57BL6 mice fed a normal chow or
HFD with or without dietary nitrate for 12 weeks. n = 10/group, ANOVA (∗p < 0 05).
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measured as calories/mouse/day, mice fed the HFD con-
sumed more than those fed the normal chow diet. Neither
of these reached statistical significance, and dietary nitrate
supplementation had no effect on food consumption with
either diet (data not shown).
There was noticeable adipocyte hypertrophy in mice con-
suming the HFD compared to normal chow; however, addi-
tion of dietary nitrate had no effect on this (Figure 1(b)).
Hepatic fat accumulation as evidenced by lipid droplets
was also higher in mice consuming the HFD compared
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Figure 2: (a) Fasting glucose tolerance testing in C57BL6 mice fed a normal chow or HFD with or without dietary nitrate for 12 weeks.
n = 10/group, ANOVA (∗p < 0 05). (b) Representative immunohistochemistry images (depicted by brown staining, magnification at
200×) and the ratio of renal proximal tubule expression of SGLT2 in C57BL6 mice fed a normal chow or HFD with or without
dietary nitrate for 12 weeks (n = 5/group; FOV: field of view).
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to normal chow, and once again, this was not affected by
dietary nitrate (Figure 1(c)).
3.2. The Effect of Dietary Nitrate on the Development of Diet-
Induced Glucose Intolerance. Mice fed the HFD for 12 weeks
had significantly impaired glucose tolerance compared to
mice receiving the normal chow diet. Addition of dietary
nitrate had no significant effect on glucose tolerance with
either diet (Figure 2(a)). As SGLT2 is responsible for glucose
reabsorption and may influence blood glucose levels, we
assessed SGLT2 expression in the renal proximal tubules in
a subset of mice (5/group). We observed no difference in
renal proximal tubule SGLT2 expression, regardless of the
diet they were receiving (Figure 2(b)).
3.3. The Effect of Dietary Nitrate on Markers of Metabolic
Activity and Energy Expenditure. There was no significant
difference in white or brown adipose tissue expression of
AMPK, p-AMPK, ACC, or p-ACC in mice fed the normal
chow or HFD, with or without the addition of nitrate (data
not shown). UCP1 expression was not detectable in white
adipose tissue in any of the dietary treatment groups (data
not shown) and was not significantly different in brown
adipose tissue between the normal chow and HFD, with or
without nitrate (data not shown).
Energy expenditure as assessed via running wheel use
revealed no significant difference between any of the die-
tary treatment groups in the amount of exercise as assessed
via the total distance or the total revolutions over a 3-day
period (Table 1).
3.4. The Effect of Dietary Nitrate Supplementation on
Circulating Nitrate and Nitrite. Circulating serum nitrate
and nitrite levels were increased in mice receiving the nitrate
supplemented diet, and this appeared most pronounced and
significant in the HFD group (Figures 3(a) and 3(b)).
3.5. The Effect of Dietary Nitrate on Production of Short-
Chain Fatty Acids. There was no effect of any dietary treat-
ment on caecum levels of acetate (Figure 4(a)). Caecum con-
centrations of butyrate and propionate were significantly
reduced in the nitrate-supplemented normal chow and both
the HFD and nitrate-supplemented HFD compared to nor-
mal chow diet alone (Figures 4(b) and 4(c)).
4. Discussion
Inorganic nitrate was originally believed to be an inert by-
product of NO metabolism that was readily excreted by the
body but could be potentially toxic and carcinogenic when
given in supraphysiological doses [14]. However, nitrate is
present in the diet, particularly green leafy vegetables [15],
and discovery of the nitrate-nitrite-NO conversion pathway
in mammals [16] has highlighted the possibility of using this
system to enhance or supplement the body’s NO supplies.
This may be particularly important in disease states where
NO levels are compromised, such as CVD and T2DM. Inor-
ganic nitrate has previously been shown to improve risk fac-
tors for CVD such as endothelial dysfunction and blood
pressure in humans [17], protect against myocardial
ischaemia-reperfusion injury in mice [18], reverse features
of the metabolic syndrome in the eNOS knockout mouse
[8] and mice having undergone ovariectomy [19], prevent
endothelial dysfunction, and improve plaque composition
and stability in the ApoE−/− mouse [7].
In the present study, we examined the potential for long-
term dietary nitrate supplementation to prevent develop-
ment of the metabolic syndrome in the C57BL6 mouse fed
a high-fat diet for 12 weeks. Despite seeing significant
increases in circulating nitrate and nitrite in mice receiving
the nitrate-supplemented diets, this did not result in
improvements in any features of the metabolic syndrome.
Mice on the HFD gained more weight and had significant
glucose intolerance compared to their normal chow-fed
counterparts, and addition of nitrate to their diet did not
ameliorate this. Furthermore, there was no effect of dietary
nitrate on white or brown adipose tissue expression of pro-
teins involved in thermogenesis or fatty acid oxidation.
Moreover, dietary nitrate significantly reduced caecum con-
centrations of the short-chain fatty acids, butyrate, and pro-
pionate, regardless of whether the mice were consuming a
normal chow or high-fat diet.
Obesity, caused by excessive accumulation of white
adipose tissue, is a major component of the metabolic syn-
drome. White adipose tissue is the primary site of energy
storage and hormone and cytokine release. In contrast,
brown adipose tissue is important for both basal and thermal
energy expenditure [20]. A previous in vitro study has shown
that cGMP promotes a healthy expansion and browning of
white adipose tissue to so-called “brown-like” or “brite” cells
that have been suggested to have both antiobesity and
insulin-sensitising effects [21]. As cGMP is a target of NO,
it is possible that dietary nitrate treatment, through conver-
sion via the nitrate-nitrite-NO pathway, could target cGMP
in adipose tissue and enhance this browning phenomenon.
Through a series of in vitro and in vivo studies, Roberts
et al. found out that this browning effect of nitrate was medi-
ated through both a cGMP and protein kinase-G mediated
Table 1: Energy expenditure as assessed by running wheel distance
and revolutions over a 3-day period.
NC
+NaCl
NC
+NaNO3
HFD
+NaCl
HFD
+NaNO3
Distance (meters)
Day 1 185± 44 156± 24 104± 12 91± 39
Day 2 198± 51 206± 41 157± 22 111± 50
Day 3 221± 32 267± 65 238± 26 139± 60
Average
206± 38 213± 48 166± 20 114± 50
Revolutions
Day 1 502± 126 412± 63 417± 59 296± 133
Day 2 528± 136 547± 108 417± 59 296± 133
Day 3 591± 87 684± 135 633± 69 369± 159
Average
541± 106 548± 99 442± 52 302± 131
Mean ± SEM (n = 5/group).
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mechanism that was further enhanced in hypoxia [9, 22].
Despite this, in the present study, we saw no beneficial effects
of dietary nitrate on weight gain, adipocyte hypertrophy, or
hepatic lipid accumulation, as well as no difference in
markers of thermogenesis or fatty acid oxidation in the white
or brown adipose tissue of these mice. While the reason for
the lack of beneficial effect in our study is unknown, it is
possible that differences in the dose of nitrate, mouse model,
and severity of disease (vascular versus metabolic endpoints)
or study duration may have all contributed. This is supported
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Figure 3: Serum (a) nitrate and (b) nitrite concentrations in C57BL6 mice fed a normal chow or HFD with or without dietary nitrate for 12
weeks. n = 10/group, ANOVA (∗p < 0 05).
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Figure 4: Caecum (a) acetate, (b) butyrate, and (c) propionate concentrations in C57BL6 mice fed a normal chow or HFD with or without
dietary nitrate for 12 weeks. n = 10/group, ANOVA (∗p < 0 05).
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by our previous study where we saw dose-dependent effects
of dietary nitrate on endothelial function and atherosclerotic
plaque size and composition [7] and the known negative
cross talk that exists between the nitrate-nitrite-NO and
eNOS pathways [23]. It is also possible that the benefits of
dietary nitrate are more apparent in a disease model that
specifically targets the endogenous eNOS pathway, resulting
in detrimental effects on the vasculature, as seen in the
eNOS−/− and ApoE−/− mouse models [7, 8]. In addition,
despite seeing significant increases in circulating nitrate and
nitrite suggesting conversion of the dietary nitrate to nitrite
by the mouse oral bacteria, subsequent tissue uptake of
nitrate/nitrite may have been impaired or reduced, limiting
any potential beneficial effects. While future studies with
higher doses or supplementation with nitrite are warranted,
in the present study, we chose to use a moderate dose of die-
tary nitrate, which is both physiologically relevant and repre-
sents what could be achieved through a diet rich in fruits and
vegetables, in contrast to nitrite, which is predominately
found in processed meats [15].
An alternate possibility for the lack of beneficial effect
may be related to the reduction we observed in the caecum
concentrations of the SCFAs butyrate and propionate. SCFAs
are produced by the gut microbiome and have been associ-
ated with several key metabolic processes, including adipos-
ity, food intake, lipid metabolism, glucose homeostasis, and
insulin resistance [24, 25]. Gut-derived propionate is used
in the hepatic synthesis of odd-chain fatty acids, which are
associated with a reduced risk of T2DM [26], and butyrate
supplementation has been shown to improve insulin sensitiv-
ity and increase energy expenditure in mice fed a HFD [27].
In the present study, we saw significant reductions in both
propionate and butyrate in the HFD-fed mice compared to
normal chow-fed mice, which support these HFD-fed mice
developing features of the metabolic syndrome. Unexpect-
edly, however, dietary nitrate supplementation was unable
to prevent this reduction in the HFD-fed mice and, in fact,
significantly reduced the levels of these two important SCFA
in mice fed the normal chow diet. This may partly explain the
lack of beneficial effect we observed on development of the
metabolic syndrome, although we acknowledge that 16S
RNA sequencing and analysis to confirm gut remodeling
would further support this.
In conclusion, despite previous studies suggesting that
dietary nitrate supplementation has beneficial effects on risk
factors associated with CVD and T2DM, we observed no
beneficial effect on the development of the metabolic syn-
drome in mice fed a HFD for 12 weeks. Although the mech-
anisms for this are unknown, it may be partly attributable to
reductions in the concentration of the important SCFAs
butyrate and propionate. Future studies investigating differ-
ent doses and duration as well as intervention after disease
has been established are warranted.
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